Core Viewpoint - Aier Eye Hospital reported stable growth in its half-year results, with significant increases in outpatient volume and revenue across major business segments, driven by enhanced medical quality and new service offerings [1][2][3]. Financial Performance - In the first half of 2025, Aier Eye Hospital achieved operating revenue of 11.507 billion yuan, a year-on-year increase of 9.12%, and a net profit attributable to the parent company of 2.040 billion yuan, up 14.30% [2]. - The operating net cash flow grew by 19.65% to 3.402 billion yuan [2]. Business Growth Drivers - The outpatient volume reached 9.2483 million visits, reflecting a year-on-year growth of 16.47%, indicating an acceleration compared to the full year of 2024 [2]. - The company introduced multiple new surgical techniques, enhancing medical quality and patient satisfaction, particularly in refractive surgery [3][4]. Strategic Initiatives - Aier Eye Hospital established an MDT group for presbyopia management and opened presbyopia clinics to cater to the aging population, identifying a new growth opportunity [3]. - The "1+8+N" strategy is being advanced, with a total of 355 domestic hospitals and 240 outpatient departments, alongside 169 overseas eye centers and clinics, creating a global medical service network [3]. Technological Advancements - The introduction of new surgical technologies, including the latest robotic-assisted refractive surgery equipment, has improved operational efficiency and patient outcomes [4]. - The company is focusing on integrating AI into its operations, enhancing data utilization to drive business intelligence and operational efficiency [5]. Organizational Development - Aier Eye Hospital has initiated organizational changes to enhance management efficiency and resource sharing across regions, with a focus on talent acquisition and training [6]. - The company has successfully recruited over 700 professionals, including eye specialists and optical technicians, to strengthen its workforce [6]. Market Outlook - The eye care service market is expected to continue expanding, driven by increasing public awareness of eye health and the demand for high-quality medical services [2][6]. - Analysts maintain a positive outlook on Aier Eye Hospital's long-term growth potential, emphasizing its position as an industry leader [6].

1 / 7 | | 爱尔眼科医院（重庆沙坪坝）有限公司 | 控股子公司 | 其他应收款 | 391.95 | 1,308.77 | 1,057.49 | 643.23 | 往来款 | 非经营性往来 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 安乡爱尔眼科医院有限公司 | 控股子公司 | 其他应收款 | 296.33 | 144.30 | 168.94 | 271.68 | 往来款 | 非经营性往来 | | | 北京开创医拓科技有限公司 | 控股子公司 | 其他应收款 | 80.67 | 853.13 | 799.09 | 134.71 | 往来款 | 非经营性往来 | | | 北流爱尔眼科医院有限公司 | 控股子公司 | 其他应收款 | 114.74 | 387.41 | 463.18 | 38.98 | 往来款 | 非经营性往来 | | | 常宁爱尔眼科医院有限公司 | 控股子公司 | 其他应收款 | 30.58 | 414.86 | 445.44 | - | 往来款 | 非经营性往来 | | | 大连爱尔眼科医院有 ...

| | | 爱尔眼科医院集团股份有限公司 2025 年半年度募集资金存放与实际使用情况的专项报告 本公司及董事会全体成员保证公告内容的真实、准确、完整，没有虚假记载、误导性 陈述或重大遗漏。 一、募集资金基本情况 （一）募集资金到位情况 1、2017 年非公开发行股票募集资金到位情况 经中国证券监督管理委员会《关于核准爱尔眼科医院集团股份有限公司非公开 发行股票的批复》（证监许可【2017】1999 号）核准，并经深圳证券交易所同意， 公司于 2017 年 12 月非公开发行人民币普通股（A 股）62,328,663 股，每股发行价 格人民币 27.60 元，募集资金总额为人民币 1,720,271,098.80 元，扣除与发行有关的 费用人民币 19,534,873.65 元后的实际募集资金净额为人民币 1,700,736,225.15 元。 2017 年 12 月 19 日，上述非公开发行股票募集资金划转入本公司募集资金监管指定 账户，募集资金到位情况经中审众环会计师事务所（特殊普通合伙）予以验证并出 具众环验字(2017)010172 号验资报告。 2、2021 年向特定对象发行股票募集资金到位情况 根 ...

本公司及董事会全体成员保证公告内容的真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 爱尔眼科医院集团股份有限公司《2025 年半年度报告》全文及摘要于 2025 年 8 月 27 日在中国证监会指定的创业板信息披露网站上披露，敬请投资者注意 查阅。 特此公告。 爱尔眼科医院集团股份有限公司董事会 2025 年 8 月 26 日 证券代码：300015 股票简称：爱尔眼科 公告编号：2025-059 爱尔眼科医院集团股份有限公司 2025 年半年度报告披露提示性公告 ...

证券代码：300015 证券简称：爱尔眼科 公告编号：2025-063 监事会认为：董事会编制和审核公司 2025 年半年度报告的程序符合法律、 行政法规和中国证监会的规定，报告内容真实、准确、完整地反映了公司 2025 年上半年经营的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 此项议案以 3 票同意、0 票反对、0 票弃权获得通过。 爱尔眼科医院集团股份有限公司 第六届监事会第二十六次会议决议公告 本公司及监事会全体成员保证公告内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 爱尔眼科医院集团股份有限公司（以下简称"公司"）第六届监事会第二十 六次会议于 2025 年 8 月 26 日以通讯表决方式召开，会议通知于 2025 年 8 月 21 日以邮件方式送达，会议由监事会主席宁俊萍女士召集主持，应到监事 3 人，实 到监事 3 人，会议的召开符合《公司法》和《公司章程》的有关规定，会议合法、 有效。经审议，本次会议一致通过如下议案： 一、《2025年半年度报告》及《2025年半年度报告摘要》 具体内容详见公司在巨潮资讯网（www.cninfo.com.cn）上刊登的《2025 年 ...

Group 1 - The company reported a net profit of 2.051 billion yuan for the first half of the year, representing a year-on-year growth of 0.05% [1] - The operating revenue for the first half reached 11.507 billion yuan, showing a year-on-year increase of 9.12% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 2.04 billion yuan, with a year-on-year growth of 14.30% [1] Group 2 - The company plans not to distribute cash dividends, issue bonus shares, or increase capital using reserves [1]

本公司及董事会全体成员保证公告内容的真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 爱尔眼科医院集团股份有限公司（以下简称"公司"）第六届董事会第四十次 会议于 2025 年 8 月 26 日以现场表决与通讯表决相结合的方式召开，会议通知于 2025 年 8 月 21 日以邮件方式送达，会议由董事长陈邦先生召集。应到董事 7 人， 实到董事 7 人，会议的召开符合《公司法》和《公司章程》的有关规定，会议合 法、有效。经审议，本次会议一致通过如下议案： 一、《2025 年半年度报告》及《2025 年半年度报告摘要》 经审议，董事会认为：公司严格按照相关法律、行政法规和中国证监会、深 圳证券交易所的相关规定，编制了公司 2025 年半年度报告全文及摘要，报告内 容真实、准确、完整地反映了公司 2025 年半年度的实际情况，不存在任何虚假 记载、误导性陈述或者重大遗漏。 该议案已经公司第六届董事会审计委员会审议通过。 具体内容详见公司在巨潮资讯网（www.cninfo.com.cn）上刊登的《2025 年 半年度报告》及《2025 年半年度报告摘要》。 证券代码：300015 股票简称：爱尔眼科 公告编号 ...

爱尔眼科医院集团股份有限公司 2025 年半年度报告全文 爱尔眼科医院集团股份有限公司 2025 年半年度报告 【2025 年 8 月】 1 爱尔眼科医院集团股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人陈邦、主管会计工作负责人刘多元及会计机构负责人(会计主 管人员)赵琳声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 公司半年度报告涉及的未来计划等前瞻性陈述，不构成公司对投资者的实 质承诺，请投资者注意风险。 公司面临的风险和应对措施详见本报告"第三节 管理层讨论与分析"之 "十、 公司面临的风险和应对措施"的内容。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | . | | --- | | 4 | | 第一节 | 重要提示、目录和释义 2 | | --- | --- | | 第二节 | 公司简介和主要财务指标 16 | | 第三节 | 管理层讨论与分 ...

Core Viewpoint - Aier Eye Hospital Group reported a revenue of 60.26 billion RMB for Q1 2025, reflecting a year-on-year growth of 15.97% and a net profit of 10.50 billion RMB, up 16.71% from the previous year [1] Financial Performance - Total revenue for Q1 2025: 60.26 billion RMB, a 15.97% increase year-on-year [1] - Net profit: 10.50 billion RMB, a 16.71% increase year-on-year [1] - Non-recurring net profit: 10.60 billion RMB, a 25.78% increase year-on-year [1] - Current ratio: 1.615 [1] - Quick ratio: 1.481 [1] - Debt-to-asset ratio: 33.30% [1] Stock Performance - Stock price as of August 26, 2025: 13.83 RMB, up 0.58% [1] - Turnover rate: 1.64% [1] - Trading volume: 1.3036 million hands [1] - Trading amount: 1.794 billion RMB [1] - Net inflow of main funds: 85.99 million RMB, accounting for 4.79% of trading volume [1] - Large single net inflow: 6.32 million RMB, accounting for 0.35% of trading volume [1] - Large order net inflow: 79.67 million RMB, accounting for 4.44% of trading volume [1] - Medium order net outflow: 2.76 million RMB, accounting for 0.15% of trading volume [1] - Small order net outflow: 83.23 million RMB, accounting for 4.64% of trading volume [1] Company Overview - Aier Eye Hospital Group was established in 2003 and is located in Changsha [2] - The company primarily engages in health-related services [2] - Registered capital: 932.54 million RMB; paid-in capital: 923.68 million RMB [1][2] - Legal representative: Chen Bang [1] Investment and Intellectual Property - Aier Eye Hospital has invested in 380 companies [2] - Participated in 29 bidding projects [2] - Holds 102 trademark registrations and 69 patents [2] - Possesses 15 administrative licenses [2]

Market Overview - The medical services sector experienced a decline of 2.4% on August 26, with Sunlight Nuohe leading the drop [1] - The Shanghai Composite Index closed at 3868.38, down 0.39%, while the Shenzhen Component Index closed at 12473.17, up 0.26% [1] Individual Stock Performance - Notable gainers included Tongce Medical, which rose by 2.38% to a closing price of 48.26, and Lanwei Medical, which increased by 0.66% to 10.66 [1] - Conversely, Sunlight Nuohe saw a significant decline of 9.88%, closing at 72.10, while Hite Bio fell by 7.32% to 55.06 [2] Trading Volume and Capital Flow - The medical services sector saw a net outflow of 2.199 billion yuan from institutional investors, while retail investors contributed a net inflow of 1.11 billion yuan [2][3] - The trading volume for key stocks varied, with Aier Eye Hospital recording a significant outflow of 859.905 million yuan from institutional investors [3] Summary of Key Stocks - Aier Eye Hospital: Closing price 13.83, down 0.58%, with a trading volume of 1.3036 million shares [1] - Sunlight Nuohe: Closing price 72.10, down 9.88%, with a trading volume of 81,300 shares [2] - Hite Bio: Closing price 55.06, down 7.32%, with a trading volume of 145,600 shares [2]